ARGX share price fell sharply after a futility finding resulted in the discontinuation of a pending Phase 3 trial. SueWallSt notifies investors of a pending investigation.

NEW YORK, Oct. 8, 2026 /PRNewswire/ — argenx SE (NASDAQ: ARGX) stock dropped more than 10% in pre-market trading on October 8, 2026, when the Company halted its Phase 3 UNITY study of subcutaneous Vyvgart in Sjögren’s disease for futility. If you bought ARGX and are now holding a loss, this investigation concerns your shares. ARGX investors who lost money are encouraged to submit their loss details now. You may also contact Joseph E. Levi, Esq. via email at jlevi@SueWallSt.com or by telephone at (888) SueWallSt.

ARGX issued a press release announcing that an independent committee’s interim analysis found that the Phase 3 UNITY study was unlikely to meet its primary endpoint, and argenx said it would discontinue the study.

The same morning, argenx also reported positive Phase 2 results for FB102 in celiac disease. ARGX shares fell anyway. SueWallSt notifies investors of a pending investigation into potential securities law violations on behalf of argenx shareholders who suffered losses in the decline.

ARGX shareholders hit by the October 8 sell-off can request a no-cost review of their losses or call (888) SueWallSt.

WHY SUEWALLST: SueWallSt is powered by Levi & Korsinsky LLP. Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

Frequently Asked Questions About the ARGX Investigation

Q: How much did ARGX stock drop?A: Shares fell approximately $96.73 per share, or about 10.42% in pre-market trading on October 8, 2026, and continued to fall further by midday. Investors who purchased shares at allegedly inflated prices and suffered losses may be eligible to seek compensation.

Q: Which statements are being investigated as potentially misleading?A: The investigation concerns whether argenx made materially false or misleading statements regarding the UNITY study and the development outlook for subcutaneous Vyvgart in Sjögren’s disease. When the Company disclosed that the study would be discontinued for futility, the stock price declined sharply.

Q: What do ARGX investors need to do right now?A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery. No immediate action is required to remain eligible to participate in the investigation.

Q: What documents do I need to participate?A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.

Q: What if I already sold my ARGX shares — can I still recover losses?A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought ARGX and sold at a loss may still participate in the investigation.

Q: What if I live outside the United States?A: U.S. securities fraud investigations generally cover purchases on U.S. exchanges regardless of the investor’s country of residence.

Q: What does it cost me to participate?A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in any resulting action, these matters are generally handled on a contingency basis, with any attorneys’ fees and expenses subject to court approval.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@SueWallSt.com
Tel: (888) SueWallSt
Fax: (212) 363-7171

Attorney Advertising. Prior results do not guarantee similar outcomes.

View original content to download multimedia:https://www.prnewswire.com/news-releases/argenx-investigation-notice-suewallst-notifies-investors-of-pending-investigation-into-argenx-argx-302902808.html

SOURCE SueWallSt.com